Published on 12 Oct 2021 on Simply Wall St. via Yahoo Finance

Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) Intrinsic Value Is Potentially 96% Above Its Share Price

In this article we are going to estimate the intrinsic value of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by estimating the company's future cash flows and discounting them to their present value. We will take advantage of the Discounted Cash Flow (DCF) model for this purpose. There's really not all that much to it, even though it might appear quite complex.

We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

Check out our latest analysis for Allogene Therapeutics